18. Spinocerebellar degeneration
59 clinical trials,   78 drugs   (DrugBank: 28 drugs),   44 drug target genes,   59 drug target pathways

Searched query = "Spinocerebellar degeneration", "SCD", "Spinocerebellar ataxia type I", "SCA1", "Spinocerebellar ataxia type II", "SCA2", "Spinocerebellar ataxia type III", "SCA3", "Machado-Joseph disease", "Spinocerebellar ataxia type VI", "SCA6", "Spinocerebellar ataxia type VII", "SCA7", "Spinocerebellar ataxia type X", "SCA10", "Spinocerebellar ataxia type XII", "SCA12", "Dentatorubural pallidoluysian atrophy", "Dentatorubropallidoluysial atrophy", "DRPLA", "Naito-Koyanagi disease", "Friedreich ataxia", "FRDA", "Ataxia with vitamin E deficiency", "AVED", "Early-onset ataxia with ocular motor ataxia and hypoalbuminemia", "EOAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
6 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04192136
(ClinicalTrials.gov)
September 3, 20206/12/2019NAD+ and Exercise in FANAD+ Precursor Supplementation With Exercise Training to Increase Aerobic Capacity in Friedreich's AtaxiaFriedreich Ataxia 1Dietary Supplement: Nicotinamide Riboside;Dietary Supplement: Placebo;Other: Exercise InterventionChildren's Hospital of PhiladelphiaNational Institutes of Health (NIH)Recruiting10 Years40 YearsAll72N/AUnited States
2EUCTR2017-002163-17-ES
(EUCTR)
08/04/202023/01/2020MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Nicotinamide
INN or Proposed INN: NICOTINAMIDE
RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical FacultyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2;Phase 3Spain;Austria;Germany;United Kingdom
3NCT03761511
(ClinicalTrials.gov)
March 202027/11/2018Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich AtaxiaA Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicentre Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich AtaxiaFriedreich AtaxiaDrug: Nicotinamide;Drug: PlaceboRWTH Aachen UniversityAssistance Publique - Hôpitaux de ParisNot yet recruiting18 YearsN/AAll225Phase 2Austria;France;Germany;Italy;Spain;United Kingdom
4EUCTR2017-002163-17-GB
(EUCTR)
21/01/202031/10/2019Use of Nicotinamide for the Treatment of Patients with Friedreich's Ataxia.A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICH´S ATAXIA (NICOFA) - NICOFA Friedreich's ataxia.Friedreich ataxia is the most frequent early-onset autosomal recessive hereditary ataxia. It is caused by a pathological expansion of a GAA repeat in the first intron of the frataxin gene (FXN) and results in decreased levels of FXN protein. FXN deficiency results in a relentlessly progressive neurodegenerative condition which frequently presents around puberty. Patients gradually lose coordination, become dysarthric and are frequently wheelchair-bound as adolescents.
MedDRA version: 20.0;Level: PT;Classification code 10017374;Term: Friedreich's ataxia;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Trade Name: Nicotinamide
Product Name: Nicotinamide
INN or Proposed INN: Nicotinamide
Other descriptive name: SUB09246MIG
RWTH Aachen University, Center for Translational & Clinical Research Aachen (CTC-A)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2;Phase 3Spain;Austria;Germany;United Kingdom
5EUCTR2017-002163-17-AT
(EUCTR)
04/09/201901/08/2019A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Nicotinamide
INN or Proposed INN: NICOTINAMIDE
RWTH Aachen University represented by the Rector himself, represented by the Dean of the Medical FacultyNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2;Phase 3Austria;Germany
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2017-002163-17-DE
(EUCTR)
25/10/201820/11/2017A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA.A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTICENTRE STUDY OF THE EFFICACY AND SAFETY OF NICOTINAMIDE IN PATIENTS WITH FRIEDREICHS ATAXIA. - NICOFA Friedreich Ataxia;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Nicotinamide
INN or Proposed INN: NICOTINAMIDE
RWTH Aachen University represented by the Center for Translational & Clinical Research Aachen (CTC-A)NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
225Phase 2;Phase 3Spain;Austria;Germany;United Kingdom